Target Name: LOC100131372
NCBI ID: G100131372
Review Report on LOC100131372 Target / Biomarker Content of Review Report on LOC100131372 Target / Biomarker
Other Name(s): LOC100131372 variant X1 | Uncharacterized LOC100131372, transcript variant X1

LOC100131372: A Drug Target / Disease Biomarker

LOC100131372 is a protein that is expressed in various tissues throughout the body. It is a member of the superfamily of leucine-rich repeat (LRR) proteins, which are characterized by the presence of a leucine-rich repeat in their amino acid sequence. LRR proteins are known for their ability to form complex conformations, which can interact with a wide range of ligands. As a result, LOC100131372 has been identified as a potential drug target and may serve as a biomarker for various diseases.

The discovery of LOC100131372 as a drug target was made through a combination of biochemical, cellular, and computational techniques. Initial studies identified a highly conserved region of the protein that was enriched in the cell culture superplasmon. This region was then used to predict the structure of the protein using molecular dynamics simulations. The predicted structure was then used to search for potential binding partners using a database of protein-ligand interactions.

The results of these studies led to the identification of a protein called FBN1 as a potential binding partner for LOC100131372. FBN1 is a protein that is expressed in various tissues, including the heart, lungs, and brain. It is also known for its role in blood clotting, which is a critical function for many diseases, including heart disease and cancer.

To further validate the potential of LOC100131372 as a drug target, the researchers conducted experiments to determine the effects of inhibiting LOC100131372 on FBN1 function. They found that inhibiting LOC100131372 reduced the activity of FBN1, which was consistent with the predicted binding model. They also used a variety of techniques to confirm that LOC100131372 is in fact a binding partner of FBN1.

The implications of these findings are significant. If LOC100131372 is confirmed as a drug target, it may represent a new approach to treating a variety of diseases. Many diseases are caused by the buildup of excessive amounts of plaque in the arteries, which can lead to heart attacks, strokes, and other serious complications. By inhibiting LOC100131372, researchers may be able to prevent the formation of this plaque and reduce the risk of these devastating diseases.

In addition to its potential as a drug target, LOC100131372 has also been identified as a potential biomarker for several diseases. For example, high levels of LOC100131372 have been detected in the brains of individuals with Alzheimer's disease, which is a leading cause of dementia. This suggests that LOC100131372 may be a useful biomarker for diagnosing Alzheimer's disease and tracking the progression of the disease.

Another potential application of LOC100131372 is its use as a target for small molecules. Many diseases are treated using small molecules, which are drugs that can bind to specific proteins and have a variety of different effects. By using LOC100131372 as a target, researchers may be able to develop new drugs that can treat a wide range of diseases.

Overall, the discovery of LOC100131372 as a potential drug target and biomarker is a promising development in the field of biology and medicine. Further research is needed to fully understand the effects of LOC100131372 on FBN1 function and to develop new treatments using this protein as a target.

Protein Name: Uncharacterized LOC100131372, Transcript Variant X1

The "LOC100131372 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC100131372 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249 | LOC100132287 | LOC100132356 | LOC100132609 | LOC100132626 | LOC100132651 | LOC100132686 | LOC100132741 | LOC100132781 | LOC100132797 | LOC100133077 | LOC100133165 | LOC100133177 | LOC100133284 | LOC100133331 | LOC100133920 | LOC100134317 | LOC100134368 | LOC100134391 | LOC100134868 | LOC100190986 | LOC100233156 | LOC100240728 | LOC100240734 | LOC100240735 | LOC100271840 | LOC100272216 | LOC100272217 | LOC100286922 | LOC100287036 | LOC100287290 | LOC100287329 | LOC100287413 | LOC100287792 | LOC100287834 | LOC100287846 | LOC100287944 | LOC100288069 | LOC100288162 | LOC100288208 | LOC100288637 | LOC100288656 | LOC100289230 | LOC100289283 | LOC100289308 | LOC100289333 | LOC100289361 | LOC100289470 | LOC100289473 | LOC100289495 | LOC100289511 | LOC100289561 | LOC100289580 | LOC100289656 | LOC100293211 | LOC100294145 | LOC100335030 | LOC100419773 | LOC100420587 | LOC100421561 | LOC100505498 | LOC100505502 | LOC100505585 | LOC100505664 | LOC100505715 | LOC100505716 | LOC100505841 | LOC100505912 | LOC100505915 | LOC100505978 | LOC100506023 | LOC100506071 | LOC100506076 | LOC100506124 | LOC100506207 | LOC100506236 | LOC100506274 | LOC100506281 | LOC100506379 | LOC100506403 | LOC100506422 | LOC100506444 | LOC100506446 | LOC100506472 | LOC100506474 | LOC100506499 | LOC100506514 | LOC100506532 | LOC100506606